Sequence Variation in PPARG May Underlie Differential Response to Troglitazone

Thiazolidinediones (TZDs) are peroxisome proliferator–activated receptor-γ (PPARG) agonists used to treat type 2 diabetes. TZDs can also be used to reduce rates of type 2 diabetes in at-risk individuals. However, a large fraction of TZD-treated patients (30–40%) do not respond to TZD treatment with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wolford, Johanna K., Yeatts, Kimberly A., Dhanjal, Sharanjeet K., Black, Mary Helen, Xiang, Anny H., Buchanan, Thomas A., Watanabe, Richard M.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2005
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2923445/
https://ncbi.nlm.nih.gov/pubmed/16249460
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares